SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-231628
Filing Date
2017-07-20
Accepted
2017-07-20 07:02:32
Documents
5
Period of Report
2017-07-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d424837d8k.htm 8-K 27841
2 EX-99.1 d424837dex991.htm EX-99.1 27250
3 EX-99.2 d424837dex992.htm EX-99.2 27408
4 EX-99.3 d424837dex993.htm EX-99.3 9192
5 GRAPHIC g424837g41x77.jpg GRAPHIC 3902
  Complete submission text file 0001193125-17-231628.txt   98627
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37449 | Film No.: 17973373
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1